➢ Computerization, robotic light microscopy, multiple fiber-optic communications, and digital imaging are among the technologies contributing to the modernization of digital pathology. Healthcare information technology (IT) helps physicians in maintaining optimal workflow, along with allowing them to meet the continuously changing patient expectations.
➢ The Aperio ePathAccess software offered by Leica Biosystems enables users to share digital pathology images and case data with experts outside the IT network. Further, frequent advancements in whole-slide imaging (WSI) technology, software applications, LIS/LIMS interface, and high-speed networking are allowing pathologists to fully integrate digital pathology into their workflows.
➢ Further, the growing use of microarrays and predictive models, such as API algorithms and hybrid models, is bolstering the demand for digital image analysis. A computer-aided diagnosis integrates image processing with the concepts of physics and mathematics, and computational algorithms for disease diagnosis, anatomical evaluation, and disease progression quantification and risk assessment.
➢ Thus, the increasing popularity of computer-aided systems is supporting the digital pathology market growth.
➢ Based on product, the digital pathology market is segmented into scanner, software, storage, and communication system. The scanner segment is further bifurcated into integrated and standalone. The scanner segment held the largest market share in 2022. However, the software segment is expected to register the highest CAGR during the forecast period. Digital pathology software solutions are used for image analysis and data restoring.
➢ Companies such as Visiopharm and Indica Labs provide software and solutions for digital pathology. ➢
➢
Based on type, the digital pathology market is bifurcated into human pathology and veterinary pathology. The human pathology segment is likely to hold a larger market share in 2022. Furthermore, the same segment is expected to record a faster CAGR during 2022–2028. The market for the human pathology segment is driven by the increasing number of cancer research projects and a rising number of collaborations among research institutes, universities, and pathology laboratories.
➢ Based on application, the digital pathology market is segmented into disease diagnosis, drug discovery, teleconsultation, and training & education. The drug discovery segment is likely to hold the largest market share in 2022.
➢ Furthermore, the same segment is expected to record the highest CAGR during 2022–2028. The central benefit of digital pathology in pharmaceutical research is the ability to apply image analysis algorithms to reduce time and efforts required for subject interpretations.
➢ This is critically important to automate dull tasks such as counting cells of interest or estimating protein expression in immunohistochemical assays.
➢ Based on end user, the digital pathology market is segmented into pharma & biotech companies, hospitals, and academics. In 2022, the pharma & biotech companies segment is likely to hold the largest share of the market. Furthermore, the same segment is expected to register the highest CAGR from 2022 to 2028. ➢ The increasing use of digital pathology in drug discovery studies and drug toxicology testing is the major factor driving the market for the pharma & biotech companies segment. Biotechnology companies also use digital pathology in biobanking, biopharmaceutical studies, molecular assays, and individualized medicine development.
